Evaluation of Fecal Colonization with Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae and Risk Factors among Cancer Patients in Eastern Iran

Document Type : Original Research

Authors
P. Askari 1
F. Hakimi 2
M. Moghanni 3
A. R. Sebzari 4
M. H. Namaei 5
1 Department of Microbiology, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
2 Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
3 Faculty of Health, Birjand University of Medical Sciences, Birjand, Iran
4 Radiation Oncology, Clinical Research Development Unit (CRDU), ValiAsr Hospital, Birjand University of Medical Sciences, Birjand, Iran
5 e. Infectious Diseases Research Center, Birjand University of Medical Sciences(BUMS), Birjand, Iran.
10.52547/iem.7.4.277
Abstract
Backgrounds: This research aimed to estimate the prevalence of extended-spectrum b-lactamase-producing Enterobacteriaceae (ESBL-PE) in stool samples of patients with different types of cancer.

Materials and Methods: Stool samples or deep rectal swabs were collected from cancer cases from January 2017 to December 2018. After species identification, in order to detect ESBL-PE, double-disk synergy test (DD test) was used. Disk diffusion procedure was conducted to determine the susceptibility of bacteria to antimicrobials. Lastly, antibiotic resistance genes including bla genes were characterized via polymerase chain reaction (PCR).

Findings: Among 100 patients enrolled in this study, 50 (50%) were ESBL carriers. Escherichia coli was the most prevalent bacterium isolated (85%). Genotyping of EBSL-PE encoding genes using PCR showed that the prevalence rates of blaCTX-M and blaCTX-M-15 genes were 94 (47 of 50) and 90% (45 of 50), respectively, which were higher than those of blaTEM (80%, 40 of 50) and blaSHV genes (34%, 17of 50). There was no significant association between ESBL-PE fecal carriage and age (p= .68), sex (p = .49), time of diagnosis (p= .21), antibiotic therapy for the past three months (p= .77), and history of chemotherapy (p= .49). Finally, it was determined that cancer type was an associated risk factor for ESBL-PE fecal carriage in cancer patients.

Conclusion: This research emphasizes regular bacterial monitoring, and that antibiotic stewardship plans ought to be performed among cancer patients to prohibit further spread of ESBL-PE with confined therapeutic options.

Keywords

Subjects

1. Lin L, Jia L, Fu Y, Zhao R, Huang Y, Tang C, et al. A comparative analysis of infection in patients with malignant cancer: a clinical pharmacist consultation study. Journal of infection and public health. 2019;12(6):789-93. . https://doi.org/10.1016/j.jiph.2019.03.021
2. Jiang A-M, Shi X, Liu N, Gao H, Ren M-D, Zheng X-Q, et al. Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology Center in Western China. BMC Infectious Diseases. 2020;20(1):1-12. https://doi.org/10.1186/s12879-020-05181-6
3. Mahamat OO, Lounnas M, Hide M, Dumont Y, Tidjani A, Kamougam K, et al. High prevalence and characterization of extended-spectrum ß-lactamase producing Enterobacteriaceae in Chadian hospitals. BMC infectious diseases. 2019;19(1):1-7. http://doi.org/10.1186/s12879-019-3838-1
4. Ali T, Ali I, Khan NA, Han B, Gao J. The growing genetic and functional diversity of extended spectrum beta-lactamases. BioMed research international. 2018;2018. https://doi.org/10.1155/2018/9519718
5. ElMahallawy HA, Zafer MM, Amin MA, Ragab MM, Al-Agamy MH. Spread of carbapenem resistant Enterobacteriaceae at tertiary care cancer hospital in Egypt. Infectious Diseases. 2018;50(7):560-4. https://doi.org/10.1080/23744235.2018.1428824
6. Medboua-Benbalagh C, Touati A, Kermas R, Gharout-Sait A, Brasme L, Mezhoud H, et al. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae strains is associated with worse outcome in patients hospitalized in the pediatric oncology unit of Beni-Messous Hospital in Algiers, Algeria. Microbial Drug Resistance. 2017;23(6):757-63. https://doi.org/10.1089/mdr.2016.0153
7. Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière M. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. European journal of clinical microbiology & infectious diseases. 2013;32(7):841-50. https://doi.org/10.1007/s10096-013-1819-7
8. Arnan M, Gudiol C, Calatayud L, Liñares J, Dominguez M, Batlle M, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. European journal of clinical microbiology & infectious diseases. 2011;30(3):355-60. https://doi.org/10.1007/s10096-010-1093-x
9. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, et al. Bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. Journal of antimicrobial chemotherapy. 2010;65(2):333-41. https://doi.org/10.1093/jac/dkp411
10. Kim Y-J, Jung SM, Kang J, Ryoo SM, Sohn CH, Seo D-W, et al. Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia. Internal and emergency medicine. 2019;14(3):433-40. https://doi.org/10.1007/s11739-018-02015-x
11. Marin M, Gudiol C, Ardanuy C, Garcia-Vidal C, Calvo M, Arnan M, et al. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. Journal of Infection. 2014;69(5):417-23. https://doi.org/10.1016/j.jinf.2014.05.018
12. SG S, Nath DR. Prevalence of ESBL and Amp C producing Enterobacteriaceae in a tertiary care cancer hospital in South India with special reference to E. coli and Klebsiellapneumoniae. https://doi.org/10.9790/0853-1802042530
13. Clinical, Institute LS. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute Wayne, PA; 2017.
14. Joo E-J, Kim SJ, Baek M, Choi Y, Seo J, Yeom J-S, et al. Fecal carriage of antimicrobial-resistant Enterobacteriaceae in healthy Korean adults. J Microbiol Biotechnol. 2018;28:1178-84. https://doi.org/10.4014/jmb.1801.12060
15. Montazeri EA, Khosravi AD, Saki M, Sirous M, Keikhaei B, Seyed-Mohammadi S. Prevalence of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Causing Bloodstream Infections in Cancer Patients from Southwest of Iran. Infection and Drug Resistance. 2020;13:1319. https://doi.org/10.2147/idr.s254357
16. Calatayud L, Arnan M, Liñares J, Dominguez M, Gudiol C, Carratalà J, et al. Prospective study of fecal colonization by extended-spectrum-β-lactamase-producing Escherichia coli in neutropenic patients with cancer. Antimicrobial agents and chemotherapy. 2008;52(11):4187-90. https://doi.org/10.1128/aac.00367-08
17. Golzarri MF, Cornejo-Juárez P, Chora-Hernández LD, Vilar-Compte D. Colonization by fecal extended-spectrum b-lactamase-producing Enterobacteriaceae and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery. 2019. https://doi.org/10.1016/j.ajic.2019.01.020
18. Christophy R, Osman M, Mallat H, Achkar M, Ziedeh A, Moukaddem W, et al. Prevalence, antibiotic susceptibility and characterization of antibiotic resistant genes among carbapenem-resistant Gram-negative bacilli and yeast in intestinal flora of cancer patients in North Lebanon. Journal of infection and public health. 2017;10(6):716-20. https://doi.org/10.1016/j.jiph.2016.10.009
19. Cornejo-Juárez P, Suárez-Cuenca JA, Volkow-Fernández P, Silva-Sánchez J, Barrios-Camacho H, Nájera-León E, et al. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies. Supportive Care in Cancer. 2016;24(1):253-9. https://doi.org/10.1007/s00520-015-2772-z
20. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. Journal of Infection. 2007;55(3):254-9. https://doi.org/10.1016/j.jinf.2007.04.007
21. Moghanni M, Ghazvini K, Farsiani H, Namaei MH, Derakhshan M, Yousefi M, et al. High prevalence of sequence type 131 isolates producing CTX-M-15 among extended-spectrum β-lactamase-producing Escherichia coli strains in northeast Iran. Journal of global antimicrobial resistance. 2018;15:74-8. https://doi.org/10.1016/j.jgar.2018.05.016
22. Bourouis A, Belhadj O. Multidrug-resistant phenotype and isolation of a Novel SHV-beta-Lactamase variant in a clinical isolate of Enterobacter cloacae. Journal of Biomedical Science. 2015;22(1):1-7. https://doi.org/10.1186/s12929-015-0131-5
23. Namaei MH, Yousefi M, Ziaee M, Salehabadi A, Ghannadkafi M, Amini E, et al. First report of prevalence of CTX-M-15-producing Escherichia coli O25b/ST131 from Iran. Microbial Drug Resistance. 2017;23(7):879-84. https://doi.org/10.1089/mdr.2016.0272
24. Hassuna NA, Khairalla AS, Farahat EM, Hammad AM, Abdel-Fattah M. Molecular characterization of Extended-spectrum β lactamase-producing E. coli recovered from community-acquired urinary tract infections in Upper Egypt. Scientific reports. 2020;10(1):1-8. https://doi.org/10.1038/s41598-020-59772-z
Infection Epidemiology and Microbiology
Volume 7, Issue 4
November 2021
Pages 277-287